Jazz Pharmaceuticals (JAZZ) was upgraded to a 'Buy' recommendation by TheStreet.com's quantitative service today. Let's check out the price charts and technical indicators to see if they are in agreement.
More from Investing
If this market is ever going to top, it seems likely it will have to occur on good news since no amount of bad news seems to matter.
The company has been transitioning from a transactional hardware sales model to a subscription software model.
The RMPIA rose 3.2% for May and 3.3% for the first five months of 2020.
Let's check in on the charts of this telecommunications networking equipment company.